Clinical Trial Update: A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating eptinezumab for chronic or episodic migraine in children and adolescents aged 6 to 17 is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• VYEPTI (eptinezumab)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Migraine | Phase 3 | Status: RECRUITING